Engineering Confidence in Your Drug Delivery Devices
From discovery to delivery, the world’s leading pharmaceutical companies select Phillips Medisize to help them engineer and manufacture their life-enhancing and lifesaving drug delivery devices. We leverage our 60 years of CDMO experience to design, develop and produce patient-centric devices, including parenteral, inhalation and ocular drug delivery devices. Additionally, the 2025 Vectura acquisition expanded our offering to include inhaled drug development for small molecules, biologics, complex combinations and generic products for pMDI, DPI, nasal inhaler and nebulization devices.
Pharmaceutical Services
Phillips Medisize has the expertise and experience to create design strategies for all stages of development, from clinical trials to small- and large-scale commercial production.
Platform Products
Phillips Medisize offers customizable platform products to accelerate development timelines, help reduce risk and enhance cost efficiencies.
Featured Resources
Article
Drug Delivery Evolution Drives Complexity in Quality Control
As pen injectors, autoinjectors, on-body injectors and other drug delivery devices grow more complex, quality control becomes more complicated. Learn more.
Publication
Drug Development and Delivery – Phillips Medisize: Pen Injector Appeals to a Range of Customers
The injection market is currently dominated by pen injectors for insulin delivery, but autoinjectors are becoming more common and in a broader range of indications. Read.
Publication
Pharma Technology Focus: Open-Inhale-Close Multidose DPI Platform
Discover how Phillips Medisize helps pharmaceutical companies reduce development risk and accelerate time to market with scalable dry powder inhaler platform solutions. This article explores the Open‑Inhale‑Close (OIC) multidose DPI and the integrated formulation, device, and manufacturing expertise behind it. Read.